Forgot password

Not a Member?

Our Advocacy Efforts
AAHIVM Advocacy:
AAHIVM has a special Committee on PrEP, monitoring new science and policy developments on the issue.  The committee is working in conjunction with CDC on the subject, and will work to promote the final guidance from CDC when it is issued.
Conference Report for NATAP by Jules Levin on Rectal TDF Gel PrEP/Oral Duration of Protection Study 05.19.2014
A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate
Letter from AAHIVM Board Chair to the FDA Advisory Committee Considering Gilead Science’s application for use of Truvada for PrEP
Report from Journal of Infectious Diseases on HIV-1 Drug Resistance in the iPrEx Pre-Exposure Prophylaxis Trial